Visterra, Inc. Adds $8 Million, Ex-AMAG Pharmaceuticals, Inc. Execs, To Begin Clinical Push For Flu Antibody
Published: Dec 02, 2013
Visterra has spent four years designing and fine-tuning an antibody that it thinks can combat all types of influenza. Now it’s pocketed some cash and filled out a revamped management team to take that drug into the clinic.
Cambridge, MA-based Visterra has added $8.1 million in venture dollars to its bank account, representing the third and final tranche from a $34.2 million Series A round that the company began raising last year.
Help employers find you! Check out all the jobs and post your resume.